A negative impact for TP53 mutations on the survival of patients with MDS del(5q) as well as the lower sensitivity of TP53 mutated clones to lenalidomide treatment was also reported in a recent cohort [553]. This evidence concerns the gene TP53 and myelodysplastic syndrome.